The Company received a Japanese patent certificate for Improving the pharmacokinetic performance of TMB-365 using histidine modification technology. The patent is titled “ENGINEERING PH-DEPENDENT ANTIGEN BINDING ACTIVITY INTO ANTI-HIV ANTIBODIES WITH IMPROVED PHARMACOKINETICS” under the patent number 7397528.
The previous patent of TMB-365 was LM52 Glycan Modification technology, which has now been approved by the United States, Japan, Germany, the United Kingdom, France, Spain, Italy, China, Taiwan, and other countries.
Japan is the first country to approve this patent application for improving the pharmacokinetic performance of TMB-365 using histidine modification technology. Prolonging its blood half-life will eventually allow TMB-365 to maintain its effective drug blood concentration for a longer period of time, making it a long-acting monoclonal antibody drug. Patent applications have been filed in major countries or regions around the world, and the patent protection period can be until 2040.